Ahead Therapeutics opens a 1.4M€ funding round
The company develops a platform able to retrain the immune system to deal with autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, type-A diabetes or celiac’s disease.
Ahead Therapeutics is a technology company from Institut Català de Nanociència i Nanotecnologia (ICN2) that works to develop a therapy able to cure autoimmune diseases. The company has developed a platform to re-educate the immune system through biomimetics and nanotechnology, imitating the process that happens millions of times a day in a healthy organism. In other words, their treatment is based on informing the immunological system about a mistake to interrupt the attacks on its own tissues, thus generating a tolerance against a specific autoantigen but maintaining the systemic immunity active.
This technology has the potential to allow treatment without secondary effects that do not need to be taken chronically and can become a definitive treatment for many diseases of the immune system. The first trials on animal models have demonstrated that the drugs created by Ahead Therapeutics may reverse multiple diseases such as multiple sclerosis, rheumatoid arthritis, type-A diabetes, or celiac’s disease.
Up until now, various leading international research institutions have positively validated their technology and have already closed collaboration agreements with big pharmaceutical companies. To keep going, the company has opened a funding round through the platform Capital Cell. Starting at 1.000 euros, anyone has the possibility of becoming an investor at Ahead Therapeutics.
Their immediate goal is to put the technology to trial to find a cure for myasthenia gravis, a rare disease without treatment. Once the technology is validated on humans successfully on the rest of the products in the pipeline, among them is the development of a specific drug for type-A diabetes.